Acquisition Speculation Fuels Viking Therapeutics Stock Surge

Shares of Viking Therapeutics experienced significant upward momentum, climbing 8.1% to reach $33.90 amid renewed market speculation about potential acquisition activity in the obesity treatment sector. Investor enthusiasm was clearly demonstrated through trading volume that surged 47% above average levels, reaching 4.4 million shares.

The biotech firm has demonstrated impressive performance in recent weeks, accumulating gains exceeding 15% and hitting an intraday peak of $35.45 during the latest session. This upward movement has elevated the company’s market capitalization to approximately $3.8 billion as market participants position themselves ahead of the scheduled October 22 release of third-quarter financial results.

Recent strategic moves within the pharmaceutical industry have intensified acquisition discussions. Two substantial transactions have particularly captured market attention: Novo Nordisk’s $5.2 billion purchase of Akero Therapeutics and... Read more...